Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Camila Annicchino de Andrade"'
Autor:
Tomás Reinert, Susana Ramalho, Vivian Castro Antunes de Vasconcelos, Leonardo Roberto Silva, Ana Elisa Ribeiro da Silva, Camila Annicchino de Andrade, Maria Beatriz de Paula Leite Kraft, Guilherme Portela Coelho, Jovana Mandelli, Monique Binotto, Cesar Cabello, Geisilene Russano de Paiva Silva, José Bines, Carlos H. Barrios, Matthew J. Ellis, Marcia Silveira Graudenz
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Introduction: Mutations in the ESR1 gene (ESR1m) are important mechanisms of resistance to endocrine therapy in estrogen receptor–positive (ER+) metastatic breast cancer and have been studied as a potential therapeutic target, as well as a predicti
Externí odkaz:
https://doaj.org/article/a2a2a7904620495981a86df29964b925
Autor:
Camila Annicchino de Andrade, César Cabello, Monique Binotto, Tomás Reinert, Geisilene Rp Silva, Jovana Mandelli, Leonardo Roberto da Silva, Guilherme Palermo Coelho, Márcia Silveira Graudenz, Maria Beatriz Pl Kraft, José Bines, Matthew J. Ellis, Carlos Barrios, Ana Elisa Ribeiro da Silva, Vivian Ca Vasconcelos, Susana Ramalho
Publikováno v:
Cancer Research. 80:P2-11
Introduction: Mutations in the ESR1 gene (ESR1m) are important mechanisms of resistance to endocrine therapy (ET) in estrogen receptor-positive (ER+) advanced breast cancer and have been recognized as a prognostic and predictive biomarker as well as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::264859ef63a6ccad450f1b84f52fbe50
https://doi.org/10.1158/1538-7445.sabcs19-p2-11-08
https://doi.org/10.1158/1538-7445.sabcs19-p2-11-08
Autor:
Maria Beatriz de Paula Leite Kraft, Susana Ramalho, Renato Zochio Torresan, Antonio Luiz Frasson, Fabricio Brenelli, Tomás Reinert, Luiz Carlos Zeferino, Ana Elisa Ribeiro da Silva, Leonardo Roberto da Silva, Matthew J. Ellis, Vivian Castro Antunes Vasconcelos, Alessandra Borba Anton de Souza, César Cabello, Camila Annicchino de Andrade
Publikováno v:
Breast cancer research and treatment. 186(3)
Neoadjuvant endocrine therapy (NET) has been shown to be effective in ER-positive/HER2-negative breast cancer in clinical trials. However, adoption in clinical practice is still limited. Real-world data may provide useful insights into effectiveness,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02207aa630f127e35995d33dda50e427
https://pubmed.ncbi.nlm.nih.gov/33543355
https://pubmed.ncbi.nlm.nih.gov/33543355